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Sir,
We read with interest the paper by Polterauer et al (2010) in
which they evaluated the prognostic value of lymph node density
(LND) in patients with lymph node-positive cervical cancer. LND
is defined as the ratio of the number of metastatic lymph nodes
to the total number of lymph nodes removed. They showed that
LND410% is associated with an impaired disease-free and overall
survival. Lymph node involvement and lymph vascular space
involvement have always been noted to be a poor prognostic factor
in cancer of the cervix (Pecorelli, 2006), and thus this confirms the
fact that the higher the number of lymph nodes involved,
the worse the prognosis of the patient becomes. The benefit of
using LND could be that it also incorporates the extent of surgical
staging. Indeed, it is probably true that when you perform a
complete lymph node dissection instead of a sampling you have
more chance of finding all involved lymph nodes. However, there
is more to it than positive lymph nodes and surgical skills.
Although the authors gave the mean/median number of
removed lymph nodes and positive lymph nodes for all patients,
we were not able to discern this information for the LNDp10% or
LND410% group separately. We believe that this information is
pivotal in a study that examines the ratio of both parameters. In a
ratio, both the numerator and denominator have an equal role. The
authors state that they performed a systemic lymphadenectomy in
all patients. This means that the mean/median number of removed
lymph nodes cannot be statistically different in both groups. As a
consequence, only the denominator will become important, and
thus the number of positive lymph nodes will become the
prognostic factor. If for any reason the total number of lymph
nodes removed in both groups is different, then one must question
the reasons why. Did the surgeon stop the operation prematurely
because during the operation he/she discovered bulky involved
lymph nodes? This would make a complete systemic lymphade-
nectomy redundant, as the patient is already known to be lymph
node positive based on these few lymph nodes. This is generally
accepted as an indication for (chemo-)radiotherapy, and the
combination of a radical surgery and pelvic (chemo-)radiotherapy
will increase therapy-related morbidity (Quinn et al, 2006). Maybe
the pathologist stopped looking intensively for other lymph nodes
because he/she already found several positive lymph nodes.
Second, with respect to the technique used, they referred to a
previous study in which a laparoscopic pelvic lymph node staging
was described (Polterauer et al, 2008). In this study, patients were
included between 1995 and 2007 and, remarkably, the median
number of lymph nodes was 15, being more than 3 lymph nodes
less than in the present study. Does this implicate a learning curve
related to the laparoscopic technique used? If yes, once more a
surgical bias is introduced.
Third, we question the cutoff value and how it was established.
The authors mentioned that this was based on preliminary data
from a study by Ooki et al (2007). We wonder how well
oesophageal cancer can be compared with cervical cancer. Both
organs are located in completely different anatomic regions, with a
different lymph vessel drainage system and lymph node distribu-
tion. Did the authors try different cutoff points or was the 10%
cutoff the only value examined? If the authors tried different cutoff
points, one could argue that the authors should have used an
independent validation set to validate this cutoff point.
Fourth, with a median of 18.5 lymph nodes (range 12–27),
Polterauer et al demonstrated that they routinely performed
complete lymph node dissections. As the ratio of the median
number of involved lymph nodes (n¼2) to the median number of
removed lymph nodes (n¼18.5) was 10.8%, removing one or two
lymph nodes would more or less determine whether the patient
belonged to the category of patients with LNDp10% or LND
410%. This would implicate that the surgeon could influence to
which prognostic group the patient will belong. After all, it suffices
to remove more lymph nodes to shift the patient from the
LND410% group to the LNDp10% group. It is contradictory that
the surgeon has to remove more ‘healthy’ lymph nodes to
‘improve’ the prognosis of the patient. With more healthy lymph
nodes the denominator will become bigger and thus the LND
smaller. This strikes us as ironic.
In conclusion, as LND is influenced by surgical technique,
anatomic circumstances and the quality and accuracy of the
pathological analysis, we believe that LND is not an objective
parameter and should not influence the decision on what kind of
adjuvant treatment should be given to a patient. We believe that
the number of positive lymph nodes is probably the true predictor,
but as the number of patients in each of the different groups (1 vs 2
vs 42) was low, the authors were unable to reach significance.
Using a ratio solved this problem by creating two arbitrary groups
of patients and by using denominators that enlarged the difference
between the numerators. Published online 23 November 2010
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